TG Therapeutics
Stock Forecast, Prediction & Price Target
TG Therapeutics (TGTX) stock Price Target by analysts
$55
Potential upside: 96.99%
TG Therapeutics price prediction
What is TG Therapeutics stock analysts` prediction?
TG Therapeutics stock forecast: Based on 1 Wall Street analysts` predicted price targets for TG Therapeutics in the last 3 months, the avarage price target is $55, with a high forecast of $NaN. The average price target represents a 96.99% change from the last price of $27.92.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
TG Therapeutics stock Price Target by analysts
Full breakdown of analysts given TG Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Edward White H.C. Wainwright | 33.33% 1/3 | 10 months ago | $55 96.99% upside | $12.93 | StreetInsider | Previous targets (2) |
Corinne Jenkins Goldman Sachs | 0% 0/1 | about 1 year ago | $20 -28.36% downside | $20.58 | TheFly | Previous targets (0) |
Edward White H.C. Wainwright | 33.33% 1/3 | over 1 year ago | $49 75.50% upside | $8.21 | StreetInsider | Previous targets (2) |
Unknown Cantor Fitzgerald | N/A | over 2 years ago | $24 -14.04% downside | $18.48 | Benzinga | N/A |
Unknown Evercore ISI | N/A | over 2 years ago | $16 -42.69% downside | $11.83 | Benzinga | N/A |
Edward White H.C. Wainwright | 33.33% 1/3 | over 2 years ago | $24 -14.04% downside | $8.46 | TheFly | Previous targets (2) |
Unknown Goldman Sachs | N/A | over 3 years ago | $5 -82.09% downside | $7.26 | Benzinga | N/A |
Mayank Mamtani Telsey Advisory | 100% 1/1 | over 3 years ago | $23 -17.62% downside | $6.92 | TipRanks Contributor | Previous targets (0) |
TG Therapeutics Financial Estimates
TG Therapeutics Revenue Estimates
TG Therapeutics EBITDA Estimates
TG Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $6.68M N/A | $2.78M -58.36% | $233.66M 8290.01% | Avg: $472.36M Low: $315.81M High: $545.61M avg. 102.15% | Avg: $616.66M Low: $504.45M High: $703.09M avg. 30.54% | Avg: $837.18M Low: $684.84M High: $954.52M avg. 35.76% | Avg: $1.05B Low: $864.06M High: $1.20B avg. 26.16% |
Net Income
% change YoY
| $-355.55M N/A | $-203.83M 42.67% | $12.67M 106.21% | Avg: $101.14M Low: $16.33M High: $151.47M avg. 698.14% | Avg: $190.59M Low: $72.76M High: $227.21M avg. 88.44% | Avg: $377.21M Low: $287.98M High: $445.93M avg. 97.90% | Avg: $513.83M Low: $392.28M High: $607.45M avg. 36.22% |
EBITDA
% change YoY
| $-342.46M N/A | $-188.14M 45.06% | $26.1M 113.87% | Avg: $-369.38M Low: $-426.65M High: $-246.95M avg. -1515.25% | Avg: $-482.21M Low: $-549.80M High: $-394.47M avg. -30.54% | Avg: $-654.66M Low: $-746.41M High: $-535.53M avg. -35.76% | Avg: $-825.97M Low: $-941.74M High: $-675.67M avg. -26.16% |
EPS
% change YoY
| -$2.69 N/A | -$1.51 43.86% | $0.09 105.91% | Avg: $0.65 Low: $0.11 High: $1.02 avg. 624.52% | Avg: $1.18 Low: $0.49 High: $1.53 avg. 81.61% | Avg: $2.54 Low: $1.94 High: $3 avg. 116.15% | Avg: $3.46 Low: $2.64 High: $4.09 avg. 36.22% |
Operating Expenses
% change YoY
| $350.66M N/A | $195.35M -44.28% | $198.89M 1.81% | Avg: $93.68B Low: $62.63B High: $108.21B avg. 47001.53% | Avg: $122.30B Low: $100.04B High: $139.44B avg. 30.54% | Avg: $166.03B Low: $135.82B High: $189.30B avg. 35.76% | Avg: $209.48B Low: $171.36B High: $238.84B avg. 26.16% |
FAQ
What is TG Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 230.18% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is 16.33M, average is 101.14M and high is 151.47M.
What is TG Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 48.65% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $315.81M, average is $472.36M and high is $545.61M.
What is TG Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 214.62% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is $0.11, average is $0.65 and high is $1.02.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering TG Therapeutics stock. The most successful analyst is Edward White whose win rate is 33.33%. He has correctly predicted 1/3 price targets.